- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library
|
|
Recombinant multi-species VTN/Vitronectin protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine VTN/Vitronectin protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The protein encoded by this gene functions in part as an adhesive glycoprotein. Differential expression of this protein can promote either cell adhesion or migration as it links cells to the extracellular matrix through a variety of ligands. These ligands include integrins, plasminogen activator inhibitor-1, and urokinase plasminogen activator receptor. This secreted protein can be present in the plasma as a monomer or dimer and forms a multimer in the extracellular matrix of several tissues. This protein also inhibits the membrane-damaging effect of the terminal cytolytic complement pathway and binds to several serpin serine protease inhibitors. This protein can also promote extracellular matrix degradation and thus plays a role in tumorigenesis. It is involved in a variety of other biological processes such as the regulation of the coagulation pathway, wound healing, and tissue remodeling. The heparin-binding domain of this protein give it anti-microbial properties. It is also a lipid binding protein that forms a principal component of high density lipoprotein. [provided by RefSeq, Aug 2020]
The Alternative Names of target: Aa1018,S-protein,Serum-spreading factor,V75,VN,VNT,VTN,Vitronectin,Vn,Vtn
Go
to VTN/Vitronectin products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-SE0548-Ag-1/ GM-Tg-hg-SE0548-Ag-2 | Human VTN/Vitronectin protein | Human |
| GM-Tg-rg-SE0548-Ag-1/ GM-Tg-rg-SE0548-Ag-2 | Rat VTN/Vitronectin protein | Rat |
| GM-Tg-mg-SE0548-Ag-1/ GM-Tg-mg-SE0548-Ag-2 | Mouse VTN/Vitronectin protein | Mouse |
| GM-Tg-cynog-SE0548-Ag-1/ GM-Tg-cynog-SE0548-Ag-2 | Cynomolgus/Rhesus macaque VTN/Vitronectin protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-SE0548-Ag-1/ GM-Tg-felg-SE0548-Ag-2 | Feline VTN/Vitronectin protein | Feline |
| GM-Tg-cang-SE0548-Ag-1/ GM-Tg-cang-SE0548-Ag-2 | Canine VTN/Vitronectin protein | Canine |
| GM-Tg-bovg-SE0548-Ag-1/ GM-Tg-bovg-SE0548-Ag-2 | Bovine VTN/Vitronectin protein | Bovine |
| GM-Tg-equg-SE0548-Ag-1/ GM-Tg-equg-SE0548-Ag-2 | Equine VTN/Vitronectin protein | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-SE0548-Ag-1/ GM-Tg-hg-SE0548-Ag-2;
GM-Tg-rg-SE0548-Ag-1/ GM-Tg-rg-SE0548-Ag-2;
GM-Tg-mg-SE0548-Ag-1/ GM-Tg-mg-SE0548-Ag-2; GM-Tg-cynog-SE0548-Ag-1/ GM-Tg-cynog-SE0548-Ag-2; GM-Tg-felg-SE0548-Ag-1/ GM-Tg-felg-SE0548-Ag-2; GM-Tg-cang-SE0548-Ag-1/ GM-Tg-cang-SE0548-Ag-2; GM-Tg-bovg-SE0548-Ag-1/ GM-Tg-bovg-SE0548-Ag-2; GM-Tg-equg-SE0548-Ag-1/ GM-Tg-equg-SE0548-Ag-2 |
| Products Name | VTN/Vitronectin protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | VTN/Vitronectin |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine VTN/Vitronectin protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab
GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.